The weekly litigation news digest is live. Subscribe now
Nicotinamide Mononucleotide Derivatives And Their Uses - EP3331894
The patent EP3331894 was granted to Metro Biotech on Feb 17, 2021. The application was filed on Aug 5, 2016 under application number EP16833957A. The patent is currently recorded with a legal status of "Opposition Rejected".
EP3331894
- Application Number
- EP16833957A
- Filing Date
- Aug 5, 2016
- Status
- Opposition Rejected
- Jun 9, 2023
- Publication Date
- Feb 17, 2021
- External Links
- Slate, Register, Google Patents
Patent Summary
Using nicotinamide mononucleotide (NMN) derivatives to boost NAD+ levels for treating diseases and improving cell survival. The derivatives are compounds that mimic NMN, a precursor to NAD+, and can increase NAD+ levels more than NMN alone. The derivatives have structures represented by formulas II and III. Administering these derivatives promotes intracellular NAD+ elevation for treating diseases associated with NAD+ biosynthesis deficiency. Applications include neurodegenerative diseases, stroke prevention, diabetes, lipid disorders, cardiovascular disease, aging, stress, drug toxicity, and retinal disorders.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Patent Citations (23) New
Patent citations refer to prior patents cited during different phases such as opposition or international search.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents